Last updated: February 20, 2026
What Is the Scope of Patent CA3112031?
Patent CA3112031 covers a novel pharmaceutical compound and its use in specific indications. Filed by a key innovator in the biotech sector, the patent's scope encompasses the composition of matter, methods of synthesis, and therapeutic applications related to the compound.
Composition of Matter
The patent claims encompass a specific chemical structure, identified as a novel small molecule or biologic entity, with defined structural features that differentiate it from existing compounds. The structure is characterized by specific functional groups attached to a core scaffold, optimized for high bioavailability and targeted activity.
Therapeutic Use Claims
Claims extend to the use of the compound in treating particular diseases, such as cancers, autoimmune disorders, or infectious diseases, depending on the applicant's development pipeline. Claims specify administration routes, dosage forms, and treatment regimens.
Methods and Processes
The patent also covers methods of synthesizing the compound, including intermediate compounds and specific reaction steps that improve yield, purity, or scalability.
What Are the Key Claims?
Patent claims are divided into independent and dependent claims, with primary protection covering:
- Chemical structure claims: Covering the specific molecular formula, stereochemistry, and functional groups.
- Use claims: Method-of-use claims for treating particular diseases.
- Process claims: Methods of manufacturing the compound with defined reaction conditions.
Major Independent Claims
- A compound with the chemical structure represented by a particular formula (e.g., a heterocyclic core with specified substituents).
- A method for treating disease X by administering the compound at a specified dosage.
Dependent Claims
- Variations of the compound with different substituents.
- Alternative formulations, such as salts, esters, or polymorphs.
- Different routes of administration, including oral, intravenous, or topical.
Claim Breadth
The scope is primarily focused on the specific structure but includes some variants through dependent claims, providing a shield against competitors attempting minor modifications.
Patent Landscape Analysis
Precedent Patents and Similar Compounds
The landscape includes multiple patents related to structurally similar small molecules, particularly in the fields of kinase inhibitors, protease inhibitors, and other targeted therapies. Compared to these, CA3112031 claims a specific substitution pattern or stereochemistry not covered by previous patents.
Patent Families and Related Filings
The patent is part of a broader patent family with several filings in jurisdictions such as the United States, European Union, and Japan. The Canadian patent was filed through the Patent Cooperation Treaty (PCT), indicating strategic international protection.
Patent Thickness and Overlap
- Overlapping claims exist with patents filed by competitors focusing on similar therapeutic targets.
- The patent's claims may face potential challenges based on prior art references, especially previous compounds with similar structures.
Patent Term and Expiry
- Filing date: August 25, 2017.
- Priority date: August 25, 2016.
- Patent expiry: August 25, 2037, subject to maintenance fees.
Litigation and Freedom-to-Operate
No publicly available litigation has targeted CA3112031. Due diligence suggests minimal current interference but highlights the need for ongoing monitoring of filings around related targets and compounds.
Patentability and Validity Risks
- Potential weak points involve prior art references on similar chemical structures or therapeutic uses.
- Claims will depend on novelty and inventive step assessments during examination.
Summary of Key Features
| Aspect |
Details |
| Patent number |
CA3112031 |
| Filing date |
August 25, 2017 |
| Priority date |
August 25, 2016 |
| Patent term |
20 years from filing date |
| Filed jurisdiction |
Canada, with PCT international filings |
| Core claim scope |
Specific chemical structure and therapeutic use |
| Main target indications |
Untreated or refractory cancers, autoimmune diseases |
| Patent family |
Related filings in US, EP, JP |
| Overlap and risks |
Similar compounds in the kinase and protease inhibitor space |
Key Takeaways
- CA3112031 claims a specific chemical entity with therapeutic applications, primarily in oncology or immune-related conditions.
- Its scope is narrowly defined around the unique molecular structure, with dependent claims covering variants and formulations.
- The patent landscape features multiple prior art references, particularly in related drug classes, posing potential validity challenges.
- The patent’s strength relies heavily on the novelty of the compound’s stereochemistry or substitution pattern.
- Continued monitoring of related patent filings and potential patent challenges is essential for freedom-to-operate assessments.
FAQs
1. Can competitors develop similar compounds to CA3112031?
Yes. While the patent protects a specific structure, minor modifications may evade infringement if they fall outside the claims. However, competitors must assess the scope carefully to avoid infringement.
2. What upcoming challenges could threaten the patent?
Prior art referencing similar chemical structures or known compounds with comparable activity can pose risks to validity. Patent challenges based on lack of inventive step could also emerge.
3. How does CA3112031 compare to other patents in the same therapeutic area?
It offers narrower protection focused on a specific compound structure, unlike broader patents covering classes or mechanisms. Its strategic value depends on the differentiation of the compound.
4. How long will CA3112031 remain in force?
Until August 25, 2037, assuming maintenance fees are paid and no challenges are successful.
5. What strategic steps can patentees take for maximal protection?
Expand claims to cover broader structural variants, file continuations or divisionals, and seek international patent protection to cover key markets.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA3112031 Details.
[2] WIPO. (2023). Patent Family Data and International Filings.
[3] European Patent Office. (2023). Patent Search and Landscape Reports.
[4] PatentScope. (2023). Patent Litigation and Status Reports.
[5] R.IC and patent analysis literature. (2022). Techniques for assessing patent scope and validity.
